Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy

• Published in: Endocrine-related cancer Vol. 22; no. 5; pp. 831 - 840
• Main Authors: Hedrick, Erik, Lee, Syng-Ook, Doddapaneni, Ravi, Singh, Mandip, Safe, Stephen
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.10.2015
• Subjects: Animals; Apoptosis - drug effects; Blotting, Western; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Proliferation - drug effects; Endoplasmic Reticulum Stress - drug effects; Female; Humans; Indoles - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Receptor Subfamily 4, Group A, Member 1 - antagonists & inhibitors; Nuclear Receptor Subfamily 4, Group A, Member 1 - genetics; Nuclear Receptor Subfamily 4, Group A, Member 1 - metabolism; Phenols - pharmacology; Reactive Oxygen Species - metabolism; RNA, Small Interfering - genetics; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; antagonists; indole derivative; NR4A1
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1530/ERC-15-0063

The orphan nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors and breast cancer cell lines. The functional activity of this receptor was investigated by RNA interference with oligonucleotides targeted to NR4A1 (siNR4A1) and by treatment with NR4A1 antagonists. Breast cancer cells were treated with NR4A1 antagonists or transfected with siNR4A. Effects on cell proliferation and apoptosis as well as specific genes associated with these responses were investigated in MCF-7, SKBR3, and MDA-MB-231 cells, and in athymic nude mice bearing MDA-MB-231 cells as xenografts. Transfection of MCF-7, MDA-MB-231, and SKBR3 breast cancer cells with siNR4A1 decreased cell proliferation and induced apoptosis in these cell lines. Transfection of breast cancer cells with siNR4A1 also decreased expression of Sp-regulated genes including survivin, bcl-2, and epidermal growth factor receptor, inhibited mTOR signaling in MCF-7 cells that express WT p53, and activated oxidative and endoplasmic reticulum stress through downregulation of thioredoxin domain-containing 5 and isocitrate dehydrogenase 1. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) are NR4A1 ligands that act as NR4A1 antagonists. Treatment with selected analogs also inhibited breast cancer cell and tumor growth and induced apoptosis. The effects of C-DIM/NR4A1 antagonists were comparable to those observed after NR4A1 knockdown. Results with siNR4A1 or C-DIMs/NR4A1 antagonists in breast cancer cells and tumors were similar to those previously reported in pancreatic, lung, and colon cancer cells. They demonstrate the potential clinical applications of NR4A1 antagonists in patients with tumors that overexpress this receptor.